These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 8067702)

  • 21. Image analysis of cellular DNA content in peritoneal fluid of patients with ovarian tumors of low malignant potential and invasive epithelial ovarian cancer.
    Guidozzi F; Szumel RC; Ball JH; Johnston DA; Katz RL; Kidd L
    Gynecol Oncol; 1996 May; 61(2):204-9. PubMed ID: 8626133
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma.
    Davidson B; Skrede M; Silins I; Shih IeM; Trope CG; Flørenes VA
    Cancer; 2007 Sep; 110(6):1264-71. PubMed ID: 17647260
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients.
    Alvarez AA; Axelrod JR; Whitaker RS; Isner PD; Bentley RC; Dodge RK; Rodriguez GC
    Gynecol Oncol; 2001 Aug; 82(2):273-8. PubMed ID: 11531279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overexpression of p53 is not a feature of ovarian granulosa cell tumors.
    Liu FS; Ho ES; Lai CR; Chen JT; Shih RT; Yang CH; Tsao CM
    Gynecol Oncol; 1996 Apr; 61(1):50-3. PubMed ID: 8626117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of prognostic markers (MiB-1, RB, and bcl-2) in the diagnosis of parathyroid tumors.
    Vargas MP; Vargas HI; Kleiner DE; Merino MJ
    Mod Pathol; 1997 Jan; 10(1):12-7. PubMed ID: 9021722
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic significance of p53 expression in ovarian granulosa cell tumors.
    Ala-Fossi SL; Mäenpää J; Aine R; Koivisto P; Koivisto AM; Punnonen R
    Gynecol Oncol; 1997 Sep; 66(3):475-9. PubMed ID: 9299263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survival of ovarian cancer patients overexpressing the tumour antigen p53 is diminished in case of MHC class I down-regulation.
    Leffers N; Lambeck AJ; de Graeff P; Bijlsma AY; Daemen T; van der Zee AG; Nijman HW
    Gynecol Oncol; 2008 Sep; 110(3):365-73. PubMed ID: 18571704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Prognosis value of p53, C-erB-2 and Ki67 proteins in ovarian carcinoma].
    Frutuoso C; Silva MR; Amaral N; Martins I; De Oliveira C; De Oliveira HM
    Acta Med Port; 2001; 14(3):277-83. PubMed ID: 11552325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. p53 expression in epithelial ovarian neoplasms: relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry.
    Henriksen R; Strang P; Wilander E; Bäckström T; Tribukait B; Oberg K
    Gynecol Oncol; 1994 Jun; 53(3):301-6. PubMed ID: 8206402
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of aggressiveness of gastrointestinal stromal tumours based on immunostaining with bcl-2, Ki-67 and p53.
    Meara RS; Cangiarella J; Simsir A; Horton D; Eltoum I; Chhieng DC
    Cytopathology; 2007 Oct; 18(5):283-9. PubMed ID: 17883690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vascular endothelial growth factor (VEGF) expression in primary tumors and peritoneal metastases from patients with advanced ovarian carcinoma.
    Gadducci A; Viacava P; Cosio S; Cecchetti D; Fanelli G; Fanucchi A; Teti G; Genazzani AR
    Anticancer Res; 2003; 23(3C):3001-8. PubMed ID: 12926153
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunohistochemical staining for Ber-EP4, p53, proliferating cell nuclear antigen, Ki-67, bcl-2, CD34, and factor XIIIa in nevus sebaceus.
    Barrett TL; Smith KJ; Williams J; Corner SW; Hodge JJ; Skelton HG
    Mod Pathol; 1999 May; 12(5):450-5. PubMed ID: 10349981
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Relationship between expressions of p53, c-erbB2 genes, proliferating cell nuclear antigen and prognosis of patients with ovarian epithelial carcinoma].
    Li JD; Li MD; Li YF; Huang X; Liu JH; Liu FY; Zhang CQ
    Ai Zheng; 2002 Mar; 21(3):292-6. PubMed ID: 12451998
    [TBL] [Abstract][Full Text] [Related]  

  • 34. p53 status is neither a predictive nor a prognostic variable in patients with advanced ovarian cancer treated with a paclitaxel-based regimen.
    Gadducci A; Cianci C; Cosio S; Carnino F; Fanucchi A; Buttitta F; Conte PF; Genazzani AR
    Anticancer Res; 2000; 20(6C):4793-9. PubMed ID: 11205220
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytologic features of ovarian tumors of low malignant potential in peritoneal fluids.
    Johnson TL; Kumar NB; Hopkins M; Hughes JD
    Acta Cytol; 1988; 32(4):513-8. PubMed ID: 3400392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunostaining of p53 protein in ovarian carcinoma: correlation with histopathological data and clinical outcome.
    Reles A; Schmider A; Press MF; Schönborn I; Friedmann W; Huber-Schumacher S; Strohmeyer T; Lichtenegger W
    J Cancer Res Clin Oncol; 1996; 122(8):489-94. PubMed ID: 8698749
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cytodiagnosis of ovarian cancer--usefulness of peritoneal washings in histological diagnosis].
    Yoh S; Nishida T; Tanaka H; Tasaki T; Matsukuma T; Kawano S; Abe T; Nishida T; Yakushiji M; Kato T
    Nihon Sanka Fujinka Gakkai Zasshi; 1984 Jan; 36(1):30-6. PubMed ID: 6699447
    [TBL] [Abstract][Full Text] [Related]  

  • 38. p53 and erbB-2 are not associated in matched cases of primary and metastatic ovarian carcinomas.
    Rodríguez-Burford C; Chhieng DC; Stockard CR; Kleinberg MJ; Barnes MN; Partridge EE; Weiss HL; Grizzle WE
    Dis Markers; 2003-2004; 19(1):11-7. PubMed ID: 14757942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of the TP53 tumour suppressor gene product and p53 auto-antibodies in the ascites of women with ovarian cancer.
    Angelopoulou K; Diamandis EP
    Eur J Cancer; 1997 Jan; 33(1):115-21. PubMed ID: 9071910
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of PAX8 and p53 is beneficial in recognizing metastatic carcinomas in pelvic washings, especially in cases with suspicious cytology.
    Xiang L; Zheng W; Kong B
    Gynecol Oncol; 2012 Dec; 127(3):595-600. PubMed ID: 22940488
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.